The Development of Immune-based Therapies Using Plant Derived Compounds to Attenu
Small Business Information
10322 BRIAR HOLLOW DR APT 7, SAINT LOUIS, MO, 63146
AbstractDESCRIPTION (provided by applicant): Secondary metabolites will be extracted from a specific plant material to identify and isolate immune active components. These components are proposed to enhance the innate and adaptive immune systems by modulating cert ain cytokine levels in white blood cells before the progression of Human Immunodeficiency Virus (HIV) to Acquired Immune Deficiency Syndrome (AIDS) occurs. The components identified will be used to develop new anti-HIV immune-based therapies. The plant mat erial containing the components with desirable immune active characteristics has been identified. The methods suitable for extraction of secondary metabolites (non-polymeric small molecules) from the plant material and antibody-based assay for testing of h uman cytokines in white blood cells have been established. Phase I of this project includes identification and isolation of immune active components from the plant extract using reverse phase High Performance Liquid Chromatography (HPLC), Ion-Exchange Chro matography (IEC), Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS). The percentage of active components in the plant will be determined. Phase II of the project will entail either large scale isolation/purification or synthesis of identified imm une active plant components to develop screens for new anti-HIV immune-based therapies both in vitro and in vivo. The therapies proposed can reduce viral load and indirectly lower the resistance of HIV to current antiviral drugs. PUBLIC HEALTH RELEV ANCE: The project seeks to isolate immune active components from specific plants that can modulate certain cytokine levels in human white blood cells which would provide an immune-based therapeutic activity to attenuate HIV progression. The end result of t his project would have substantial commercial potential as a frontline therapy and synergistic compound that can indirectly lower the resistance of HIV to current antiviral drugs. We believe that our potential product will be used either alone, as an initi al therapy for newly diagnosed patients, or in combination with current antiviral drugs.
* information listed above is at the time of submission.